UCB (OTCMKTS:UCBJF) Stock Passes Above 50 Day Moving Average - Here's What Happened

Key Points

• UCB SA's share price has surged above its 50-day moving average, last trading at $238.84, indicating potential upward momentum.
• Morgan Stanley has upgraded UCB's stock rating to "overweight", contributing to a consensus rating of "Buy" from analysts.
• The company specializes in biopharmaceuticals, focusing on treatment for neurology and immunology diseases with a strong product portfolio including Cimzia and Vimpat.

UCB SA (OTCMKTS:UCBJF - Get Free Report)'s stock price crossed above its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of $216.96 and traded as high as $238.84. UCB shares last traded at $238.84, with a volume of 53 shares trading hands.

Wall Street Analyst Weigh In

Separately, Morgan Stanley upgraded UCB to an "overweight" rating in a research note on Monday, June 23rd. One research analyst has rated the stock with a Buy rating, According to data from MarketBeat, the stock currently has a consensus rating of "Buy".

UCB Stock Up 7.4%

The stock has a 50 day moving average of $218.48 and a 200-day moving average of $191.15. The company has a debt-to-equity ratio of 0.33, a quick ratio of 0.78 and a current ratio of 1.19.

About UCB

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.